Real-World Findings Show Improvements in Migraine-Related Cognitive Symptoms Linked to Vyepti Treatment
KEY TAKEAWAYS
- More than half of patients reported improvement in migraine-related cognitive symptoms after 6 months of Vyepti treatment.
- Cognitive symptoms such as brain fog, difficulty concentrating, and task impairment were highly prevalent and bothersome at baseline.
Treatment with Vyepti (eptinezumab-jjmr; Lundbeck, Copenhagen, Denmark) was associated with improvements in migraine-related cognitive symptoms, including brain fog and difficulty with daily tasks, according to an interim analysis of the real-world INFUSE study presented at the 2026 American Academy of Neurology (AAN) Annual Meeting. At baseline, most participants reported bothersome cognitive symptoms, which according to the study authors, highlights the importance of addressing these symptoms in migraine management.
INFUSE is an ongoing prospective cohort study evaluating the real-world effectiveness of Vyepti treatment in adults with migraine who had experienced failure of ≥1 prior calcitonin gene–related peptide (CGRP)–targeted preventive therapy. Patient-reported outcomes were collected via a web-based platform. This interim analysis included patients who received 2 infusions of Vyepti and completed baseline and 6-month assessments, focusing on changes in cognitive symptoms.
Among 75 patients with baseline data, cognitive symptoms were highly prevalent: 92.0% reported brain fog, 86.7% difficulty with tasks, 81.3% difficulty reading, and 73.3% difficulty making decisions. These symptoms were frequently rated as moderately to extremely bothersome.
Key Findings
- At 6 months, 57.8% of patients with baseline brain fog reported improvement at 6 months, after 2 Vyepti infusions.
- Improvement was also reported in other domains, including difficulty making decisions (50.0%), reading (50.0%), and performing tasks (51.2%).
- Early improvements were observed as soon as 7 days after treatment initiation across cognitive symptom domains.
Source
Holecko M. Real-world improvements in cognitive symptoms after eptinezumab treatment in patients in whom ≥1 prior anti-CGRP preventive treatment had failed: 6-month results for the ongoing INFUSE study. Presented at: American Academy of Neurology Annual Meeting; April 18-22, 2026; Chicago, IL.